Chronic HCV hepatitis is a progressive disease; if not treated it progress towards liver cirrhosis, hepatocellular carcinoma and/or liver insufficiency. Different antiviral treatments are now available, whose success rate ranging from 20 to 65% of the patients, depending on factors related to the virus (viral load, genotype, etc) or to the host (gender, age, time of infections, precence of comorbidities).
Effect of combined IFN-Alpha/Ribavirin Treatment in HCV disease-related progression / D.Festi;F.Lodato;G.Mazzella;A.Colecchia. - STAMPA. - (2008), pp. 215-236.
Effect of combined IFN-Alpha/Ribavirin Treatment in HCV disease-related progression
FESTI, DAVIDE;LODATO, FRANCESCA;MAZZELLA, GIUSEPPE;COLECCHIA, ANTONIO
2008
Abstract
Chronic HCV hepatitis is a progressive disease; if not treated it progress towards liver cirrhosis, hepatocellular carcinoma and/or liver insufficiency. Different antiviral treatments are now available, whose success rate ranging from 20 to 65% of the patients, depending on factors related to the virus (viral load, genotype, etc) or to the host (gender, age, time of infections, precence of comorbidities).File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.